The mainstays of treatment for HER2-negative breast cancer are taxanes (paclitaxel and docetaxel) and anthracyclines (doxorubicin and epirubicin), which are frequently administered one after the other or in combination (Group et al., 2012). Here, ERBB2 is linked to breast cancer.